Researchers use PD-1 checkpoint drug in pursuit of a promising curative approach to HIV
The big drug developers like Gilead and GlaxoSmithKline learned years ago how to keep a lid on HIV, but researchers remain challenged by their inability to root out the latent reservoirs of virus the hide in the cells.
But now investigators are pursuing a new research track that has just demonstrated its potential in a cancer patient in France.
Doctors there were treating a lung cancer patient with HIV with Bristol-Myers Squibb’s Opdivo and observed a “drastic and persistent decrease” in the virus hidden in cells. And there may be a very simple explanation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
